Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.

ABSTRACT: PURPOSE:Asymptomatic decline in left ventricular ejection fraction (LVEF) or heart failure (HF) occurs in up to 25% of patients treated with trastuzumab and can result in incomplete breast cancer therapy. The cardiac safety of continuing trastuzumab in patients with asymptomatic LVEF decline is unknown. We report the cardiac outcomes of patients treated with trastuzumab after a significant asymptomatic LVEF decline. METHODS:Patients with HER2-positive breast cancer and asymptomatic LVEF decline to ?50%, 21 (57%) were not re-challenged, and one (3%) developed HF. More patients in the continued trastuzumab group had metastatic disease (39% vs. 5%, p?=?0.002). The final LVEF after median follow-up of 633 days was similar between patients with trastuzumab continuation versus interruption (54% vs. 56%, p?=?0.29). CONCLUSION:Continuation of trastuzumab after an asymptomatic LVEF decline to

SUBMITTER: Hussain Y 

PROVIDER: S-EPMC6494676 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature